comparing car t-cell toxicity in all and lymphoma
Published 6 years ago • 224 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
2:31
car t-cell therapy toxicities in b-cell lymphomas
-
3:43
car t-cell toxicity: crs, icans and prolonged cytopenias
-
2:44
comparing car-t products for aggressive b-cell lymphoma: axi-cel versus tisa-cel
-
2:55
car t-cell update: what’s new in dlbcl and mm?
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:29
cd5.car t-cell therapy in patients with t-cell lymphoma
-
1:39
out of specification anti-cd19 car t-cell products in aggressive b-cell lymphomas
-
59:12
car t-cell therapy: the good, the bad and the long-term 2022
-
42:45
david bartel (whitehead institute/mit/hhmi) part 1: micrornas: introduction to micrornas
-
1:08:26
understanding car t-cell therapy (november 2020)
-
1:31
price vs. performance: car t-cells
-
4:06
car t-cells in adult all
-
11:13
car t-cells in lymphoma: where are we now?
-
3:06
car-t and bites – which targets belong in clinical practice?
-
1:55
are car t-cells worth the money in lymphoma?
-
3:18
out of specification car t-cells
-
1:26
the safety and efficacy of allosct following car-t cell therapy for large b-cell lymphoma
-
1:27
car t-cells in all: an overview
-
2:27
the potential of car t-cell therapy in combination with antibodies for the treatment of all
-
2:57
the promise of allogeneic car-t cell products for the treatment of hematological malignancies
-
2:30
car-t as a new standard of care in lymphoma
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all